Skip to main content
Signal8
Launch Terminal

Candel Therapeutics, Inc. (CADL)

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc.

NASDAQ:CADLHealthcare
-3.70%$8.33
AH$8.47+1.68%vs close
Mkt Cap$637.4M
Float59.29M
O/S76.52M
Vol
$ Vol
RVOL
Inst Own64.8%
SI21.5%
Earnings
Dilution
Candel Therapeutics, Inc. logoNASDAQ:CADL$8.33-3.70%
Upcoming Catalysts
Phase Distribution
13 lead-sponsored trials·5 active·7 completed
Phase 16
Phase 25
Phase 32
(1 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Active, not recruiting

    Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

    Aglatimagene besadenovec + valacyclovir, Placebo + valacyclovir

    Prostate Cancer

    Enrollment
    711
    Start
    Sep 2011
    Primary Completion
    Aug 2024
    Completion
    Dec 2030est.
    NCT01436968
  • Phase 3
    Recruiting

    Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)

    Aglatimagene Besadenovec, Valacyclovir

    Non-squamous, Non-Small Cell Lung Cancer

    Enrollment
    500
    Start
    Jun 2026est.
    Primary Completion
    Oct 2031est.
    Completion
    Oct 2031est.
    NCT07660094
  • Phase 2
    Completed

    Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma

    CAN-2409, Valacyclovir

    Malignant Glioma, Glioblastoma Multiforme +2

    Enrollment
    52
    Start
    Mar 2007
    Primary Completion
    Dec 2015
    Completion
    Aug 2016
    NCT00589875
  • Phase 2
    Unknown status

    Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

    Aglatimagene besadenovec

    Borderline Resectable Pancreatic Adenocarcinoma

    Enrollment
    54
    Start
    Oct 2015
    Primary Completion
    Dec 2025est.
    Completion
    Jul 2026est.
    NCT02446093
  • Phase 2
    Active, not recruiting

    Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

    aglatimagene besadenovec, placebo

    Prostate Cancer

    Enrollment
    187
    Start
    May 2016
    Primary Completion
    Nov 2024
    Completion
    Dec 2026est.
    NCT02768363
  • Phase 2
    Active, not recruiting

    CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

    Aglatimagene besadenovec

    Non Small Cell Lung Cancer

    Enrollment
    90
    Start
    Oct 2020
    Primary Completion
    Dec 2024
    Completion
    Dec 2026est.
    NCT04495153
  • Phase 2
    Recruiting

    A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

    aglatimagene besadenovec + valacyclovir

    Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)

    Enrollment
    45
    Start
    Oct 2025
    Primary Completion
    Feb 2027est.
    Completion
    Feb 2027est.
    NCT07332000
  • Phase 1
    Completed

    A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors

    AdV-tk, valacyclovir

    Malignant Glioma, Recurrent Ependymoma

    Enrollment
    8
    Start
    Oct 2010
    Primary Completion
    Dec 2015
    Completion
    Jun 2021
    NCT00634231
  • Phase 1
    Completed

    AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

    AdV-tk, Valacyclovir

    Pancreatic Adenocarcinoma, Pancreatic Cancer

    Enrollment
    27
    Start
    Aug 2008
    Primary Completion
    May 2013
    Completion
    Jun 2015
    NCT00638612
  • Phase 1
    Completed

    Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas

    AdV-tk, Valacyclovir

    Malignant Glioma, Glioblastoma Multiforme +1

    Enrollment
    15
    Start
    Nov 2005
    Primary Completion
    Jan 2010
    Completion
    Jan 2011
    NCT00751270
  • Phase 1
    Completed

    Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion

    AdV-tk + valacyclovir

    Malignant Pleural Effusion, Lung Cancer +3

    Enrollment
    19
    Start
    Oct 2013
    Primary Completion
    Dec 2015
    Completion
    Feb 2018
    NCT01997190
  • Phase 1
    Completed

    Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer

    CAN-2409 + valacyclovir

    Lung Cancer

    Enrollment
    12
    Start
    May 2017
    Primary Completion
    Dec 2021
    Completion
    Sep 2023
    NCT03131037
  • Phase 1
    Completed

    GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas

    AdV-tk, Valacyclovir

    Glioma, Malignant

    Enrollment
    41
    Start
    Feb 2018
    Primary Completion
    Jun 2023
    Completion
    Jun 2023
    NCT03576612
Search ClinicalTrials.gov for “Candel Therapeutics”